NextCure Inc (NXTC) - Net Assets
Based on the latest financial reports, NextCure Inc (NXTC) has net assets worth $12.15 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($22.62 Million) and total liabilities ($10.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NextCure Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.15 Million |
| % of Total Assets | 53.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | -85.03% |
| 10-Year Change | N/A |
| Growth Volatility | 12.85 |
NextCure Inc - Net Assets Trend (2017–2025)
This chart illustrates how NextCure Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is NextCure Inc worth.
Annual Net Assets for NextCure Inc (2017–2025)
The table below shows the annual net assets of NextCure Inc from 2017 to 2025. Also explore NextCure Inc (NXTC) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $34.94 Million | -46.63% |
| 2024-12-31 | $65.47 Million | -42.78% |
| 2023-12-31 | $114.42 Million | -31.70% |
| 2022-12-31 | $167.53 Million | -28.22% |
| 2021-12-31 | $233.39 Million | -20.54% |
| 2020-12-31 | $293.72 Million | -8.64% |
| 2019-12-31 | $321.48 Million | +784.82% |
| 2018-12-31 | $-46.94 Million | -92.30% |
| 2017-12-31 | $-24.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NextCure Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41148200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.01% |
| Other Comprehensive Income | $21.00K | 0.06% |
| Other Components | $470.90 Million | 1347.62% |
| Total Equity | $34.94 Million | 100.00% |
NextCure Inc Competitors by Market Cap
The table below lists competitors of NextCure Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Milae Bioresources Co. Ltd
KQ:218150
|
$25.96 Million |
|
Inspira Technologies Oxy BHN Ltd
NASDAQ:IINN
|
$25.96 Million |
|
Bayfirst Financial Corp
NASDAQ:BAFN
|
$25.98 Million |
|
Delta Resources Ltd
V:DLTA
|
$25.98 Million |
|
Scandinavian Investment Group A/S
CO:SIG
|
$25.95 Million |
|
Nitiraj Engineers Limited
NSE:NITIRAJ
|
$25.95 Million |
|
Pusan Cast Iron Co., Ltd.
KO:005030
|
$25.95 Million |
|
Assems Inc.
KQ:136410
|
$25.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NextCure Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 65,472,000 to 34,943,000, a change of -30,529,000 (-46.6%).
- Net loss of 55,844,000 reduced equity.
- New share issuances of 22,276,000 increased equity.
- Other comprehensive income increased equity by 17,000.
- Other factors increased equity by 3,022,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-55.84 Million | -159.81% |
| Share Issuances | $22.28 Million | +63.75% |
| Other Comprehensive Income | $17.00K | +0.05% |
| Other Changes | $3.02 Million | +8.65% |
| Total Change | $- | -46.63% |
Book Value vs Market Value Analysis
This analysis compares NextCure Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.46x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-12.90 | $5.67 | x |
| 2018-12-31 | $-24.80 | $5.67 | x |
| 2019-12-31 | $245.79 | $5.67 | x |
| 2020-12-31 | $128.02 | $5.67 | x |
| 2021-12-31 | $101.41 | $5.67 | x |
| 2022-12-31 | $72.46 | $5.67 | x |
| 2023-12-31 | $49.33 | $5.67 | x |
| 2024-12-31 | $28.09 | $5.67 | x |
| 2025-12-31 | $12.29 | $5.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NextCure Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -159.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.44x
- Recent ROE (-159.81%) is below the historical average (-43.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.03 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.10 Million |
| 2019 | -10.49% | -531.54% | 0.02x | 1.11x | $-65.89 Million |
| 2020 | -11.30% | -148.32% | 0.07x | 1.04x | $-62.56 Million |
| 2021 | -29.73% | 0.00% | 0.00x | 1.04x | $-92.73 Million |
| 2022 | -41.45% | 0.00% | 0.00x | 1.10x | $-86.19 Million |
| 2023 | -54.82% | 0.00% | 0.00x | 1.12x | $-74.17 Million |
| 2024 | -85.00% | 0.00% | 0.00x | 1.24x | $-62.20 Million |
| 2025 | -159.81% | 0.00% | 0.00x | 1.44x | $-59.34 Million |
Industry Comparison
This section compares NextCure Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NextCure Inc (NXTC) | $12.15 Million | 0.00% | 0.86x | $25.95 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more